NephroPlus Q3 FY26 Results: Revenue up 31.7% YoY to ₹259.7 Cr, Adj. EBITDA up 43.0% YoY to ₹63.1 Cr
NephroPlus reported Q3 FY26 revenue of ₹259.7 crore, up 31.7% YoY. For 9M FY26, revenue was ₹733.2 crore, up 36.6% YoY. Adjusted EBITDA for Q3 FY26 increased 43.0% YoY to ₹63.1 crore, and for 9M FY26, it rose 52.1% YoY to ₹175.4 crore. Treatment volumes grew 17.7% in Q3, with international revenue contribution rising to 41.1%.
The announcement details significant financial growth in revenue and EBITDA, along with positive operational metrics and strategic market shifts, which are material factors for investors and stakeholders.
The company reported strong year-on-year growth in both revenue and Adjusted EBITDA, driven by increased treatment volumes and a favorable shift towards higher-revenue international markets. The operational metrics also show consistent growth, indicating a positive financial performance.
Nephrocare Health Services Limited (NephroPlus) has announced its un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a revenue of ₹259.7 crore for Q3 FY26, marking a significant year-on-year growth of 31.7%. For the nine months ended FY26, the revenue stood at ₹733.2 crore, an increase of 36.6% year-on-year.
This growth was primarily driven by a 17.7% increase in treatment volumes and a favorable mix shift towards international markets, where revenue per treatment is higher and contributes positively to the Return on Capital Employed (ROCE). The contribution of international revenue increased from 29.5% to 41.1% in the nine-month period, leading to a 17% uplift in revenue per treatment.
The company's Adjusted EBITDA for Q3 FY26 grew by 43.0% year-on-year to ₹63.1 crore. For the nine months of FY26, the Adjusted EBITDA was ₹175.4 crore, an increase of 52.1% year-on-year. This sustained growth in EBITDA is attributed to the increasing contribution from higher-priced international markets and the scalable India platform, which drives superior margins and ROCE.
Operational highlights include consistent growth in guest numbers and treatment counts. The number of guests served reached 36,550 by the end of 9M FY26, with approximately 2.85 million treatments performed during the same period. Revenue per treatment also saw a consistent year-on-year growth, reaching ₹2,574 in 9M FY26, indicating continued pricing momentum and a favorable mix shift.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.